Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

12.42
0.0000
Post-market: 12.36-0.0617-0.50%19:40 EDT
Volume:953.58K
Turnover:11.84M
Market Cap:3.96B
PE:33.47
High:12.53
Open:12.46
Low:12.34
Close:12.42
52wk High:15.42
52wk Low:7.02
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.65
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3711
EPS(LYR):0.2200
ROE:-881.26%
ROA:8.35%
PB:-87.25
PE(LYR):56.45

Loading ...

Amneal Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
May 20

Amneal Pharmaceuticals price target raised to $16 from $15 at Barclays

TIPRANKS
·
May 20

Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Radnet (RDNT) and Relay Therapeutics (RLAY)

TIPRANKS
·
May 20

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Amneal director Deborah M. Autor disposes 34,819 shares worth $450,537.86

Reuters
·
May 13

Amneal Q1 net income more than doubles to $78 million; net revenue rises 3.9% to $722.52 million

Reuters
·
May 08

Amneal Pharmaceuticals held annual shareholder meeting, director nominees elected

Reuters
·
May 08

Amneal Pharmaceuticals Q1 Adj. EPS $0.27 Beats $0.23 Estimate, Sales $722.519M Miss $757.228M Estimate

Benzinga
·
May 08

Amneal Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 08

Amneal Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge?

Simply Wall St.
·
Apr 30

Earning Preview: Amneal Pharmaceuticals, Inc. Q1 revenue is expected to decrease by 0.03%, and institutional views are mostly bullish

Earnings Agent
·
Apr 25

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway

Reuters
·
Apr 23

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, GE Vernova, Calix

Reuters
·
Apr 22

Why Is Amneal Pharmaceuticals Stock Gaining Today?

Benzinga_recent_news
·
Apr 22

Amneal lifts 2026 adjusted EBITDA outlook to $740 million-$770 million

Reuters
·
Apr 22

BRIEF-Kashiv Biosciences Agrees To Be Acquired By Amneal Pharmaceuticals To Create A Fully Integrated Global Biosimilar Leader

Reuters
·
Apr 22

BUZZ-Amneal rises as Kashiv BioSciences buy lifts biosimilar push, outlook

Reuters
·
Apr 22

Amneal Pharmaceuticals Shares up 3% Premarket After Annual Adj. Profit Forecast Raise, $1.1 Bln Deal to Acquire Kashiv Biosciences

THOMSON REUTERS
·
Apr 22